EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Evolving TRALI risk across apheresis and whole blood platelet products in the United States: An 18‐year American Red Cross hemovigilance analysis

Pampee P Young iD, Umesh Singh, Jonathan Webb, Mark R Looney

Transfusion · 2025

DOI: 10.1111/trf.18457 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transfusion, 2025. Verfasst von Pampee P Young und 3 weiteren Autor:innen. Beteiligte Einrichtung: Medical and Scientific Affairs, American Red Cross Biomedical Services, Washington, District of Columbia, USA. Hauptthemen laut MEDLINE: Platelet Transfusion, Transfusion-Related Acute Lung Injury, Blood Component Removal, Blood Safety. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Transfusion‐related acute lung injury (TRALI) remains a leading cause of transfusion‐associated mortality in the United States. Donor‐based mitigation has reduced TRALI risk from plasma and apheresis platelets, but the residual risk associated with whole‐blood‐derived pooled platelets is not well defined. Study Design and Methods We retrospectively analyzed transfusion reactions reported to the American Red Cross (ARC) national hemovigilance program from 1 January 2006 through 31 December 2023. Reactions were adjudicated using Canadian Consensus Conference criteria; definite or highly probable TRALI cases (levels 5–6) were included. Component distribution data served as denominators. Trends were evaluated in relation to two mitigation efforts: male‐predominant plasma (2005–2006) and HLA‐antibody screening of previously pregnant apheresis‐platelet donors (2016).

Results

Over 18 years ARC distributed 92.7 million red blood cells, 23.5 million plasma units, and 17 million platelets—including 0.87 million pooled WB‐derived platelets, 11.7 million plasma‐suspended apheresis, 1.5 million PAS apheresis, and 2.9 million pathogen‐reduced (PR) platelet‐additive solution‐3 (PAS) apheresis platelets. We identified 393 high‐probability TRALI cases. Plasma‐associated TRALI declined from 20.0 to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Platelet TransfusionTransfusion-Related Acute Lung InjuryBlood Component RemovalBlood SafetyPlateletpheresisBlood PlateletsHumansUnited StatesMaleFemaleRetrospective StudiesRed CrossBlood DonorsRisk Factors

Stichwörter der Autor:innen

TRALIdonor screeninghemovigilancepathogen reductionplatelets

Autor:innen und Institutionen

  • Medical and Scientific Affairs, American Red Cross Biomedical Services, Washington, District of Columbia, USA.
  • Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • San Francisco, Departments of Medicine and Laboratory Medicine, University of California, San Francisco, California, USA.

ORCID-Profile: Pampee P Young

Förderung

  • NIAID NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Young, P. P., Singh, U., Webb, J., & Looney, M. R. (2025). Evolving TRALI risk across apheresis and whole blood platelet products in the United States: An 18‐year American Red Cross hemovigilance analysis. Transfusion. https://doi.org/10.1111/trf.18457

Vancouver

Young PP, Singh U, Webb J, Looney MR. Evolving TRALI risk across apheresis and whole blood platelet products in the United States: An 18‐year American Red Cross hemovigilance analysis. Transfusion. 2025. doi:10.1111/trf.18457

BibTeX
@article{Young2025,
  author = {Young, Pampee P and Singh, Umesh and Webb, Jonathan and Looney, Mark R},
  title = {Evolving TRALI risk across apheresis and whole blood platelet products in the United States: An 18‐year American Red Cross hemovigilance analysis},
  journal = {Transfusion},
  year = {2025},
  doi = {10.1111/trf.18457}
}
Kostenlos starten →